|1.||Hashimoto, Ayako: 2 articles (07/2015 - 05/2007)|
|2.||Ogino, Atsushi: 1 article (07/2015)|
|3.||Kawasaki, Masanori: 1 article (07/2015)|
|4.||Nagashima, Kenshi: 1 article (07/2015)|
|5.||Takemura, Genzou: 1 article (07/2015)|
|6.||Yabuuchi, Youichi: 1 article (07/2015)|
|7.||Goto, Kazuko: 1 article (07/2015)|
|8.||Fujiwara, Hisayoshi: 1 article (07/2015)|
|9.||Kanamori, Hiromitsu: 1 article (07/2015)|
|10.||Nakagawa, Munehiro: 1 article (07/2015)|
07/01/2015 - "The purpose of this study was to examine the effect of OPC-28326 on the architectural dynamics and function of the infarcted left ventricle during the chronic stage of myocardial infarction. "
07/01/2015 - "Myocardial infarction was induced in male C3H/He mice, after which the mice were randomly assigned into two groups: a control group receiving a normal diet and an OPC group whose diet contained 0.05% OPC-28326. "
|2.||Body Weight (Weight, Body)
10/01/2001 - "Intravenous OPC-28326 had no effect on this action, even at a very high dose of 10 mg kg(-1) i.v., while yohimbine (0.1 - 0.3 mg kg(-1) i.v.) inhibited mydriasis in a dose-dependent manner, indicating that OPC-28326 was at least 100 times less potent than yohimbine in regard to the anti-mydriatic effect. "
|4.||Vascular Diseases (Vascular Disease)
05/01/2007 - "Next, the angiogenic effect of OPC-28326 was evaluated in a mouse hindlimb ischemia model. "
05/01/2007 - "Here, we investigated the effect of OPC-28326 on ischemia-induced angiogenesis. "
05/01/2007 - "OPC-28326, a selective femoral arterial vasodilator, augments ischemia induced angiogenesis."